ResMed Bull Stays Positive on Margin, Earnings -- Market Talk

Dow Jones

06/03

0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com)

(END) Dow Jones Newswires

June 03, 2025 02:51 ET (06:51 GMT)

应版权方要求，你需要登录查看该内容

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2540747982"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2540747982\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2540747982?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-06-03 14:51","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2540747982","market":"hk","top_or_hot":-1,"title":"ResMed Bull Stays Positive on Margin, Earnings -- Market Talk","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2025 02:51 ET (06:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ResMed Bull Stays Positive on Margin, Earnings -- Market Talk</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nResMed Bull Stays Positive on Margin, Earnings -- Market Talk\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-06-03 14:51</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<p>\n     0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com) \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  June 03, 2025 02:51 ET (06:51 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"RMD.AU","symbol_name":"Resmed DRC","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2540747982","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2540747982","pubTimestamp":1748933460,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. ","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{"RMD.AU":"Resmed DRC","RMD":"瑞思迈"},"translate_title":"瑞思迈牛市对利润率和盈利保持乐观——市场讨论","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"RMD":1,"RMD.AU":0.9},"content_text":"0651 GMT - ResMed's bull at Citi stays positive on the breathing-tech provider following its third-quarter update. Analyst Mathieu Chevrier raises his EPS forecasts by 3.1% for fiscal 2026 and by 3.6% for fiscal 2027 on higher gross-margin expectations. He points out in a note to clients that the company has yet to see any impact from the increasing use of weight-loss drugs. Chevrier acknowledges that there is still a live debate over whether the net impact of the drugs will turn out to be negative, but notes growth in awareness of conditions such as sleep apnea could be positive. Citi raises its target price on ResMed's Australia-listed stock by 2.3% to A$45.00. Shares closed 0.6% higher at A$37.93. (stuart.condie@wsj.com) \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  June 03, 2025 02:51 ET (06:51 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}